Company intelligence / Profile preview

Tissue Repair Ltd

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase IIB clinical trials in 2020 with data analysis finalized in March 2021, showing promising efficacy for its proprietary technology. Planning to commence pivotal Phase III trials for TR-987 in 2024, subject to FDA approval.

Therapeutic areas: Dermatology
Modalities: Topical gelimmunogenic active ingredient
Industry: Biotech

Drug pipeline

1 asset

GAM501

Unknown

Beyond the preview

Go deeper on Tissue Repair Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tissue Repair Ltd.

Explore the full profile